276 related articles for article (PubMed ID: 36831638)
1. Systems Biology Approaches for the Improvement of Oncolytic Virus-Based Immunotherapies.
Tripodi L; Sasso E; Feola S; Coluccino L; Vitale M; Leoni G; Szomolay B; Pastore L; Cerullo V
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831638
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic Immunotherapy: Can't Start a Fire Without a Spark.
Muscolini M; Tassone E; Hiscott J
Cytokine Growth Factor Rev; 2020 Dec; 56():94-101. PubMed ID: 32826166
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment.
Feola S; Russo S; Ylösmäki E; Cerullo V
Pharmacol Ther; 2022 Aug; 236():108103. PubMed ID: 34954301
[TBL] [Abstract][Full Text] [Related]
4. Arming oncolytic viruses to leverage antitumor immunity.
de Gruijl TD; Janssen AB; van Beusechem VW
Expert Opin Biol Ther; 2015 Jul; 15(7):959-71. PubMed ID: 25959450
[TBL] [Abstract][Full Text] [Related]
5. Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy.
Groeneveldt C; Kinderman P; van Stigt Thans JJC; Labrie C; Griffioen L; Sluijter M; van den Wollenberg DJM; Hoeben RC; den Haan JMM; van der Burg SH; van Hall T; van Montfoort N
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35853671
[TBL] [Abstract][Full Text] [Related]
6. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.
Jafari M; Kadkhodazadeh M; Shapourabadi MB; Goradel NH; Shokrgozar MA; Arashkia A; Abdoli S; Sharifzadeh Z
Front Immunol; 2022; 13():1012806. PubMed ID: 36311790
[TBL] [Abstract][Full Text] [Related]
7. Sharpening the Edge for Precision Cancer Immunotherapy: Targeting Tumor Antigens through Oncolytic Vaccines.
Holay N; Kim Y; Lee P; Gujar S
Front Immunol; 2017; 8():800. PubMed ID: 28751892
[TBL] [Abstract][Full Text] [Related]
8. Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia.
Wang W; Liu S; Dai P; Yang N; Wang Y; Giese RA; Merghoub T; Wolchok J; Deng L
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593618
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
Russell L; Peng KW; Russell SJ; Diaz RM
BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic viruses and their application to cancer immunotherapy.
Chiocca EA; Rabkin SD
Cancer Immunol Res; 2014 Apr; 2(4):295-300. PubMed ID: 24764576
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives.
Guo ZS; Liu Z; Kowalsky S; Feist M; Kalinski P; Lu B; Storkus WJ; Bartlett DL
Front Immunol; 2017; 8():555. PubMed ID: 28555136
[TBL] [Abstract][Full Text] [Related]
12. Current landscape and perspective of oncolytic viruses and their combination therapies.
Su Y; Su C; Qin L
Transl Oncol; 2022 Nov; 25():101530. PubMed ID: 36095879
[TBL] [Abstract][Full Text] [Related]
13. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy.
Tian Y; Xie D; Yang L
Signal Transduct Target Ther; 2022 Apr; 7(1):117. PubMed ID: 35387984
[TBL] [Abstract][Full Text] [Related]
14. Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy.
Palanivelu L; Liu CH; Lin LT
Front Immunol; 2022; 13():1038226. PubMed ID: 36755812
[TBL] [Abstract][Full Text] [Related]
15. Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies.
Gujar S; Pol JG; Kim Y; Lee PW; Kroemer G
Trends Immunol; 2018 Mar; 39(3):209-221. PubMed ID: 29275092
[TBL] [Abstract][Full Text] [Related]
16. Design and application of oncolytic viruses for cancer immunotherapy.
Ylösmäki E; Cerullo V
Curr Opin Biotechnol; 2020 Oct; 65():25-36. PubMed ID: 31874424
[TBL] [Abstract][Full Text] [Related]
17. Therapy-Induced MHC I Ligands Shape Neo-Antitumor CD8 T Cell Responses during Oncolytic Virus-Based Cancer Immunotherapy.
Murphy JP; Kim Y; Clements DR; Konda P; Schuster H; Kowalewski DJ; Paulo JA; Cohen AM; Stevanovic S; Gygi SP; Gujar S
J Proteome Res; 2019 Jun; 18(6):2666-2675. PubMed ID: 31095916
[TBL] [Abstract][Full Text] [Related]
18. Genetic modification of oncolytic viruses to enhance antitumor immunity.
Davola ME; Vito A; Wei J; El-Sayes N; Workenhe S; Mossman KL
Methods Enzymol; 2020; 635():231-250. PubMed ID: 32122548
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic viruses as therapeutic cancer vaccines.
Bartlett DL; Liu Z; Sathaiah M; Ravindranathan R; Guo Z; He Y; Guo ZS
Mol Cancer; 2013 Sep; 12(1):103. PubMed ID: 24020520
[TBL] [Abstract][Full Text] [Related]
20. Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements.
Yun CO; Hong J; Yoon AR
Front Immunol; 2022; 13():953410. PubMed ID: 36091031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
